+44.4%
GSK vs USFD
+215.4%
-171.1%
-37.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | USFD | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.5% | +0.2% | +0.3% | +0.5% |
| 7D | +1.1% | +1.7% | -0.5% | +0.9% |
| 30D | +6.3% | +10.2% | -3.8% | +4.6% |
| 3M | +1.8% | -1.5% | +3.3% | +1.9% |
| 6M | +1.7% | +27.3% | -25.7% | -2.3% |
| YTD | +6.5% | +44.0% | -37.4% | +0.2% |
| 1Y | +9.5% | +50.4% | -40.9% | +2.2% |
| 3Y | +65.3% | +153.6% | -88.3% | +40.1% |
| All | +44.4% | +215.4% | -171.1% | +15.5% |
Cumulative growth
Daily Returns
Daily percentage return beside USFD.
Daily Out/Under-Performance
Portfolio return minus USFD return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × USFD return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded USFD wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling